We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

The Neuroscience of Psychedelic Drugs: Ending Psychedelic Myths With Professor David Nutt

Article   Dec 13, 2019 | by Ruairi J Mackenzie, Science Writer for Technology Networks

 
The Neuroscience of Psychedelic Drugs: Ending Psychedelic Myths With Professor David Nutt
 
 
 

RELATED ARTICLES

The Future of Neurotechnology: What I’ve Learned As a Gen-Z, Early-stage Founder

Article

In this comment piece, Hubly Surgical CEO Casey Grage gives a perspective on her advancing career, which has seen her go from freshman to startup co-founder in just a few years.

READ MORE

Nanoparticle Drug Delivery Could Offer More Effective Pain Relief Than Opioids

Article

Historically, efforts to target the substance P (SP) neurokinin 1 receptor (NK1R), for the treatment of pain have failed. These studies had one critical flaw, whilst they were targeting the right receptor, they were focusing on the wrong location.

READ MORE

Exploring the Medicinal Benefits of Cannabis Within UK Pharmaceuticals

Article

In this article, we explore how the use of cannabis within UK pharmaceuticals is expected to change, as well as the medicinal benefits offered by cannabis, and cannabinoids.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE